Tfelt-Hansen P, Henry P, Mulder L J, Scheldewaert R G, Schoenen J, Chazot G
Neurologisk afdeling, Bispebjerg Hospital, København.
Ugeskr Laeger. 1996 Nov 4;158(45):6435-9.
A combination of lysine acetylsalicylate (equivalent to 900 mg aspirin) and 10 mg metoclopramide (LAS + MTC) was compared with oral sumatriptan (100 mg) and placebo in 421 patients with migraine in a randomized, double-blind, clinical trial. LAS + MTC was as effective as sumatriptan with a decrease in headache from severe or moderate to mild or none in 57% and 53%, respectively, for the first migraine attack treated, the primary efficacy parameter. Both treatments were better than placebo (success rate 24%, p < 0.001). LAS + MTC was better tolerated than sumatriptan (adverse events in 18% and 28%, respectively, p < 0.05).
在一项随机、双盲临床试验中,将赖氨酸乙酰水杨酸酯(相当于900毫克阿司匹林)与10毫克甲氧氯普胺的组合(LAS + MTC)与口服舒马曲坦(100毫克)及安慰剂进行了比较,共纳入421例偏头痛患者。LAS + MTC与舒马曲坦的疗效相当,在首次治疗的偏头痛发作中,主要疗效参数(头痛从重度或中度减轻至轻度或消失)的发生率分别为57%和53%。两种治疗均优于安慰剂(成功率24%,p < 0.001)。LAS + MTC的耐受性优于舒马曲坦(不良事件发生率分别为18%和28%,p < 0.05)。